The Directorate General of Foreign Trade has extended the minimum import price (MIP) for ATS-8 and Sulfadiazine API until November 30, 2026. This regulatory measure sets a price floor to protect domestic manufacturers from low-cost imports. Investors should watch how this impacts procurement costs and profit margins for pharmaceutical companies relying on these inputs.
The Directorate General of Foreign Trade (DGFT) has officially extended the minimum import price (MIP) regime for two key pharmaceutical raw materials, ATS-8 and Sulfadiazine API. These ingredients will continue to be subject to fixed price floors until November 30, 2026. Under this mandate, ATS-8 is capped at a floor price of USD 111 per kilogram, while Sulfadiazine API is held at USD 1,774 per kilogram.
This regulatory decision serves as a defensive mechanism for India’s domestic Active Pharmaceutical Ingredient (API) manufacturers. By establishing these minimum price points, the government prevents international suppliers from offloading these chemicals at aggressively low prices, which often makes it difficult for local producers to compete. Effectively, any import attempt below these specified values will face trade barriers or higher duties, ensuring that domestic production costs remain competitive.
For pharmaceutical companies that use ATS-8 and Sulfadiazine in their drug formulations, this policy creates a fixed cost structure. On the positive side, it removes price volatility, allowing companies to better plan their procurement and budgeting. However, it also means these companies are unable to benefit from lower international prices if global market rates for these ingredients fall below the DGFT-mandated floors. As a result, the cost of raw materials for manufacturers becomes predictable but rigid.
The policy aligns with India’s broader strategic focus on strengthening the domestic pharmaceutical supply chain and reducing import dependency for critical drug components. By supporting local API production, the government aims to reduce the sector’s reliance on foreign markets, which has been a priority for the industry over the past few years.
Investors tracking pharmaceutical companies should look at how this impacts gross margins. Companies that are heavy users of these specific precursors may see their material costs stabilized, but they will not be able to capitalize on potential price drops in the global market. The long-term monitorable will be whether domestic manufacturers can ramp up capacity to reliably meet the demand previously satisfied by imports, and how this price floor affects the overall pricing strategy of the downstream pharmaceutical formulations.